Vision Fund (Aiv M1) Softbank Purchases 2,033,990 Shares of Guardant Health Inc (GH) Stock

Share on StockTwits

Guardant Health Inc (NASDAQ:GH) major shareholder Vision Fund (Aiv M1) Softbank purchased 2,033,990 shares of Guardant Health stock in a transaction dated Tuesday, March 12th. The stock was bought at an average cost of $9.83 per share, for a total transaction of $19,994,121.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Shares of GH opened at $97.98 on Friday. Guardant Health Inc has a fifty-two week low of $27.04 and a fifty-two week high of $106.58. The company has a market cap of $8.48 billion and a P/E ratio of -34.99.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Tuesday, March 12th. The company reported ($0.30) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.05. The firm had revenue of $32.87 million during the quarter, compared to analysts’ expectations of $24.57 million. As a group, analysts predict that Guardant Health Inc will post -1.26 earnings per share for the current year.

Several large investors have recently made changes to their positions in GH. Temasek Holdings Private Ltd acquired a new position in shares of Guardant Health in the 4th quarter valued at $60,633,000. Orbimed Advisors LLC acquired a new position in shares of Guardant Health in the 4th quarter valued at $57,681,000. BlackRock Inc. acquired a new position in shares of Guardant Health in the 4th quarter valued at $41,894,000. Jennison Associates LLC acquired a new position in shares of Guardant Health in the 4th quarter valued at $31,700,000. Finally, Lord Abbett & CO. LLC acquired a new position in shares of Guardant Health in the 4th quarter valued at $20,024,000. 69.54% of the stock is currently owned by institutional investors.

Several brokerages recently weighed in on GH. William Blair reaffirmed an “outperform” rating on shares of Guardant Health in a research note on Wednesday. JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $42.00 to $85.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Bank of America reaffirmed a “neutral” rating and set a $60.00 target price (up from $42.00) on shares of Guardant Health in a research note on Thursday, February 28th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $72.50.

COPYRIGHT VIOLATION WARNING: “Vision Fund (Aiv M1) Softbank Purchases 2,033,990 Shares of Guardant Health Inc (GH) Stock” was originally published by Week Herald and is owned by of Week Herald. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://weekherald.com/2019/03/17/vision-fund-aiv-m1-softbank-purchases-2033990-shares-of-guardant-health-inc-gh-stock.html.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.

Further Reading: Why is cost of goods sold important?

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.